search
Back to results

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Primary Purpose

Melanoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Pembrolizumab/Vibostolimab
Pembrolizumab
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melanoma focused on measuring Programmed Cell Death-1 (PD1, PD-1), T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT)

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines Has not received any prior systemic therapy for melanoma beyond surgical resection Has had no more than 12 weeks between final surgical resection and randomization Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening Exclusion Criteria: Has ocular, mucosal, or conjunctival melanoma Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication Has not adequately recovered from major surgical procedure or has ongoing surgical complications Has received prior radiotherapy within 2 weeks of start of study intervention or has had a history of radiation pneumonitis Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease Has a known additional malignancy that is progressing or has required active treatment within the past 3 years Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis Has an active autoimmune disease that has required systemic treatment in past 2 years Has an active infection requiring systemic therapy Has had an allogenic tissue/solid organ transplant

Sites / Locations

  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123)Recruiting
  • California Pacific Medical Center - Pacific Campus ( Site 0111)Recruiting
  • UCSF Medical Center at Mission Bay ( Site 0130)Recruiting
  • Georgetown University Medical Center ( Site 0144)Recruiting
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110)Recruiting
  • Northwestern Memorial Hospital ( Site 0109)Recruiting
  • Advocate Medical Group-Oncology ( Site 0102)Recruiting
  • Comprehensive Cancer Centers of Nevada ( Site 0142)Recruiting
  • Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113)Recruiting
  • Sanford Fargo Medical Center ( Site 0127)Recruiting
  • Children's Hospital of Pittsburgh ( Site 0141)Recruiting
  • UPMC Hillman Cancer Center ( Site 0135)Recruiting
  • Sanford Cancer Center ( Site 0125)Recruiting
  • The West Clinic, PLLC dba West Cancer Center ( Site 0119)Recruiting
  • Inova Schar Cancer Institute ( Site 0103)Recruiting
  • University of Wisconsin Hospital and Clinics ( Site 0108)Recruiting
  • Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)Recruiting
  • Instituto Alexander Fleming-Alexander Fleming ( Site 0209)Recruiting
  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)Recruiting
  • Instituto de Oncología de Rosario ( Site 0206)Recruiting
  • Sanatorio Finochietto ( Site 0212)Recruiting
  • Clinica Adventista Belgrano-Oncology ( Site 0211)Recruiting
  • Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464)Recruiting
  • Calvary Mater Newcastle-Medical Oncology ( Site 1462)Recruiting
  • Melanoma Institute Australia-Clinical Trials Unit ( Site 1450)Recruiting
  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( SiRecruiting
  • Gallipoli Medical Research Foundation-GMRF CTU ( Site 1451)Recruiting
  • Cairns Hospital-Clinical Research Unit ( Site 1458)Recruiting
  • Tasman Oncology Research ( Site 1456)Recruiting
  • Royal Adelaide Hospital-RAH Cancer Centre ( Site 1457)Recruiting
  • Icon Cancer Centre Hobart ( Site 1465)Recruiting
  • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1455)Recruiting
  • One Clinical Research ( Site 1460)Recruiting
  • Ordensklinikum Linz GmbH Elisabethinen-Dermatologie ( Site 0602)Recruiting
  • Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0601)Recruiting
  • Medizinische Universitaet Innsbruck-Univ Klinik für Dermatologie, Venerologie und Allergologie ( SitRecruiting
  • Medizinische Universität Wien-Department of Dermatology ( Site 0600)Recruiting
  • Uniklinikum Salzburg-Department of Dermatology and Allergology ( Site 0604)Recruiting
  • Jessa Ziekenhuis ( Site 0656)Recruiting
  • VITAZ-Medical Oncology ( Site 0654)Recruiting
  • UZ Leuven-General Medical Oncology ( Site 0650)Recruiting
  • Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 0256)Recruiting
  • Hospital de Cancer de Londrina-Clinical Research Unit ( Site 0252)Recruiting
  • Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 0259)Recruiting
  • ANIMI - Unidade de Tratamento Oncologico ( Site 0255)Recruiting
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia ( Site 0262)Recruiting
  • A. C. Camargo Cancer Center ( Site 0258)Recruiting
  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0004)Recruiting
  • Princess Margaret Cancer Centre ( Site 0006)Recruiting
  • Oncocentro Valdivia ( Site 0307)Recruiting
  • FALP-UIDO ( Site 0303)Recruiting
  • Oncovida ( Site 0304)Recruiting
  • Clínica UC San Carlos de Apoquindo ( Site 0305)Recruiting
  • Bradfordhill-Clinical Area ( Site 0302)Recruiting
  • ONCOCENTRO APYS-ACEREY ( Site 0300)Recruiting
  • Centro de Investigación Oncológica del Norte ( Site 0308)Recruiting
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 1650)Recruiting
  • Chongqing University Cancer Hospital ( Site 1651)Recruiting
  • Fujian Provincial Cancer Hospital ( Site 1659)Recruiting
  • Sun Yat-sen University Cancer Center-melanoma ( Site 1655)Recruiting
  • Guangxi Medical University Affiliated Tumor Hospital ( Site 1668)Recruiting
  • The Third Hospital of Zhengzhou-Oncology ( Site 1653)Recruiting
  • Wuhan Union Hospital Cancer Center-Cancer Center ( Site 1664)Recruiting
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (Recruiting
  • Jiangsu Province Hospital-Oncology Department ( Site 1663)Recruiting
  • The First Affiliated Hospital of Nanchang University ( Site 1652)Recruiting
  • The First Hospital of Jilin University-Oncology ( Site 1665)Recruiting
  • Fudan University Shanghai Cancer Center ( Site 1658)Recruiting
  • Shanxi Bethune Hospital ( Site 1660)Recruiting
  • West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667)Recruiting
  • Zhejiang Cancer Hospital-Oncology ( Site 1661)Recruiting
  • Centre Hospitalier de Valence-Service de Dermatologie ( Site 0702)Recruiting
  • Hopital Claude Huriez - CHU de Lille-Clinique de Dermatologie ( Site 0700)Recruiting
  • Centre Hospitalier de Pau ( Site 0708)Recruiting
  • Gustave Roussy-Dermatologie ( Site 0713)Recruiting
  • Universitaetsklinikum Heidelberg ( Site 0765)Recruiting
  • Universitätsmedizin Mannheim ( Site 0751)Recruiting
  • Universitaetsklinikum Erlangen-Hautklinik ( Site 0750)Recruiting
  • Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0754)Recruiting
  • Medizinische Hochschule Hannover ( Site 0758)Recruiting
  • Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0761)Recruiting
  • Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 0759)Recruiting
  • Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0766)Recruiting
  • Universitätsklinikum Leipzig ( Site 0762)Recruiting
  • Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 0756)Recruiting
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0752)Recruiting
  • All India Institute of Medical Sciences-Medical oncology ( Site 1552)Recruiting
  • Artemis hospital ( Site 1551)Recruiting
  • Tata Memorial Hospital-Medical Oncology ( Site 1550)Recruiting
  • Emek Medical Center-oncology ( Site 0952)Recruiting
  • Soroka Medical Center ( Site 0953)Recruiting
  • Rambam Health Care Campus-Oncology Division ( Site 0955)Recruiting
  • Hadassah Medical Center ( Site 0951)Recruiting
  • Rabin Medical Center-Oncology ( Site 0954)Recruiting
  • Sheba Medical Center-ONCOLOGY ( Site 0950)Recruiting
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1004)Recruiting
  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1000)Recruiting
  • Instituto Tumori Giovanni Paolo II ( Site 1003)Recruiting
  • Azienda Ospedaliero Universitaria Senese ( Site 1005)Recruiting
  • Istituto Europeo di Oncologia IRCCS ( Site 1008)Recruiting
  • Nagoya University Hospital ( Site 1753)Recruiting
  • Niigata Cancer Center Hospital ( Site 1751)Recruiting
  • Seoul National University Hospital-Oncology ( Site 1600)Recruiting
  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1601)Recruiting
  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1602)Recruiting
  • Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1501)Recruiting
  • New Zealand Clinical Research (Christchurch) ( Site 1509)Recruiting
  • P3 Research - Palmerston North ( Site 1510)Recruiting
  • Harbour Cancer & Wellness ( Site 1508)Recruiting
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1061)Recruiting
  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1058)Recruiting
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (Recruiting
  • Bialostockie Centrum Onkologii ( Site 1065)Recruiting
  • Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( SiteRecruiting
  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oncologii, Chemioterapii ( Site 1064)Recruiting
  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1056)Recruiting
  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 1054)Recruiting
  • Szpital Kliniczny im. H. Swiecickiego nr 2-Oddział Kliniczny Onkologii Klinicznej i Doświadczalnej (Recruiting
  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 1161)Recruiting
  • Medical Oncology Centre of Rosebank ( Site 1160)Recruiting
  • Wilgers Oncology Centre ( Site 1154)Recruiting
  • Curo Oncology ( Site 1158)Recruiting
  • Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 1151)Recruiting
  • Cape Town Oncology Trials ( Site 1155)Recruiting
  • Cancercare Rondebosch Oncology-Clinical trials ( Site 1159)Recruiting
  • Institut Català d'Oncologia - L'Hospitalet ( Site 1202)Recruiting
  • Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1203)Recruiting
  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1204)Recruiting
  • H.R.U Málaga - Hospital General-Oncology ( Site 1201)Recruiting
  • Hospital General Universitario de Valencia ( Site 1200)Recruiting
  • Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1205)Recruiting
  • Länssjukhuset Ryhov-Onkologkliniken ( Site 1253)Recruiting
  • Karolinska Universitetssjukhuset Solna ( Site 1252)Recruiting
  • University Hospital Basel ( Site 1303)Recruiting
  • Inselspital Bern ( Site 1301)Recruiting
  • Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1307)Recruiting
  • Ospedale Regionale Bellinzona e Valli ( Site 1308)Recruiting
  • CHUV (centre hospitalier universitaire vaudois) ( Site 1304)Recruiting
  • Hôpital de Sion ( Site 1305)Recruiting
  • UniversitätsSpital Zürich-Dermatology ( Site 1300)Recruiting
  • Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 1306)Recruiting
  • Ankara City Hospital-Medical Oncology ( Site 1357)Recruiting
  • I.E.U. Medical Point Hastanesi-Oncology ( Site 1360)Recruiting
  • Hacettepe Universite Hastaneleri ( Site 1363)Recruiting
  • Liv Hospital Ankara-Oncology ( Site 1353)Recruiting
  • Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1355)Recruiting
  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1358)Recruiting
  • Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1361)Recruiting
  • Ondokuz Mayıs Universitesi-Oncology department ( Site 1359)Recruiting
  • Addenbrooke's Hospital ( Site 1400)Recruiting
  • University College London Hospital ( Site 1405)Recruiting
  • Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 1401)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Pembrolizumab/Vibostolimab

Pembrolizumab

Arm Description

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).

Adult participants receive 200 mg and adolescent participants ≥40 kg receive 2 mg/kg (up to a max of 200 mg) pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).

Outcomes

Primary Outcome Measures

Recurrence-Free Survival (RFS)
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional, or distant) as assessed by the investigator, or death due to any cause, whichever occurs first. The RFS as assessed by the investigator will be reported for all randomized participants.

Secondary Outcome Measures

Distant Metastasis-Free Survival (DMFS)
DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis, or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes. The DMFS as assessed by the investigator will be reported for all randomized participants.
Overall Survival (OS)
OS is defined as the time from randomization to death due to any cause.
Number of Participants Who Experienced at Least One Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. Change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented.
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. Change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented.
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. Change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented.

Full Information

First Posted
December 16, 2022
Last Updated
October 18, 2023
Sponsor
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05665595
Brief Title
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Official Title
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2023 (Actual)
Primary Completion Date
October 22, 2027 (Anticipated)
Study Completion Date
March 31, 2031 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma
Keywords
Programmed Cell Death-1 (PD1, PD-1), T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1560 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pembrolizumab/Vibostolimab
Arm Type
Experimental
Arm Description
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
Arm Title
Pembrolizumab
Arm Type
Active Comparator
Arm Description
Adult participants receive 200 mg and adolescent participants ≥40 kg receive 2 mg/kg (up to a max of 200 mg) pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
Intervention Type
Biological
Intervention Name(s)
Pembrolizumab/Vibostolimab
Other Intervention Name(s)
MK-7684A
Intervention Description
Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
Intervention Type
Biological
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
MK-3475, KEYTRUDA®
Intervention Description
Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
Primary Outcome Measure Information:
Title
Recurrence-Free Survival (RFS)
Description
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional, or distant) as assessed by the investigator, or death due to any cause, whichever occurs first. The RFS as assessed by the investigator will be reported for all randomized participants.
Time Frame
Up to approximately 56 months
Secondary Outcome Measure Information:
Title
Distant Metastasis-Free Survival (DMFS)
Description
DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis, or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes. The DMFS as assessed by the investigator will be reported for all randomized participants.
Time Frame
Up to approximately 72 months
Title
Overall Survival (OS)
Description
OS is defined as the time from randomization to death due to any cause.
Time Frame
Up to approximately 96 months
Title
Number of Participants Who Experienced at Least One Adverse Event (AE)
Description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time Frame
Up to approximately 15 months
Title
Number of Participants Who Discontinued Study Treatment Due to an AE
Description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time Frame
Up to approximately 12 months
Title
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
Description
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. Change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented.
Time Frame
Baseline and up to approximately 72 months
Title
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Description
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. Change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented.
Time Frame
Baseline and up to approximately 72 months
Title
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Description
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. Change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented.
Time Frame
Baseline and up to approximately 72 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines Has not received any prior systemic therapy for melanoma beyond surgical resection Has had no more than 12 weeks between final surgical resection and randomization Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening Exclusion Criteria: Has ocular, mucosal, or conjunctival melanoma Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication Has not adequately recovered from major surgical procedure or has ongoing surgical complications Has received prior radiotherapy within 2 weeks of start of study intervention or has had a history of radiation pneumonitis Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease Has a known additional malignancy that is progressing or has required active treatment within the past 3 years Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis Has an active autoimmune disease that has required systemic treatment in past 2 years Has an active infection requiring systemic therapy Has had an allogenic tissue/solid organ transplant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Toll Free Number
Phone
1-888-577-8839
Email
Trialsites@merck.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
Facility Information:
Facility Name
The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123)
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
310-231-2153
Facility Name
California Pacific Medical Center - Pacific Campus ( Site 0111)
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
415-885-8600
Facility Name
UCSF Medical Center at Mission Bay ( Site 0130)
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
415-353-7392
Facility Name
Georgetown University Medical Center ( Site 0144)
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
202-444-2198
Facility Name
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110)
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
305-243-4981
Facility Name
Northwestern Memorial Hospital ( Site 0109)
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
312-472-1234
Facility Name
Advocate Medical Group-Oncology ( Site 0102)
City
Park Ridge
State/Province
Illinois
ZIP/Postal Code
60068
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
847268-8200
Facility Name
Comprehensive Cancer Centers of Nevada ( Site 0142)
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89169
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
702-952-1242
Facility Name
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113)
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
212-731-5431
Facility Name
Sanford Fargo Medical Center ( Site 0127)
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
701-234-7551
Facility Name
Children's Hospital of Pittsburgh ( Site 0141)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
412-623-4511
Facility Name
UPMC Hillman Cancer Center ( Site 0135)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
412-623-4511
Facility Name
Sanford Cancer Center ( Site 0125)
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
605-328-8000
Facility Name
The West Clinic, PLLC dba West Cancer Center ( Site 0119)
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
901-683-0055
Facility Name
Inova Schar Cancer Institute ( Site 0103)
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
202-615-8535
Facility Name
University of Wisconsin Hospital and Clinics ( Site 0108)
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
608-265-1700
Facility Name
Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)
City
Ciudad Autónoma de Buenos Aires
State/Province
Buenos Aires
ZIP/Postal Code
C1027AAP
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5491156455799
Facility Name
Instituto Alexander Fleming-Alexander Fleming ( Site 0209)
City
Ciudad Autónoma de Buenos Aires
State/Province
Buenos Aires
ZIP/Postal Code
C1426ANZ
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
54111531493950
Facility Name
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)
City
Buenos Aires
State/Province
Caba
ZIP/Postal Code
C1431FWO
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5411529901002543
Facility Name
Instituto de Oncología de Rosario ( Site 0206)
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000KZE
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
54 9 341 5778394
Facility Name
Sanatorio Finochietto ( Site 0212)
City
Buenos Aires
ZIP/Postal Code
C1187AAN
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5491158216233
Facility Name
Clinica Adventista Belgrano-Oncology ( Site 0211)
City
Caba
ZIP/Postal Code
C1430EGF
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5491132682903
Facility Name
Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464)
City
Blacktown
State/Province
New South Wales
ZIP/Postal Code
2148
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61298455200
Facility Name
Calvary Mater Newcastle-Medical Oncology ( Site 1462)
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61249211561
Facility Name
Melanoma Institute Australia-Clinical Trials Unit ( Site 1450)
City
Wollstonecraft
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61299117336
Facility Name
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61736464311
Facility Name
Gallipoli Medical Research Foundation-GMRF CTU ( Site 1451)
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4120
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61448632604
Facility Name
Cairns Hospital-Clinical Research Unit ( Site 1458)
City
Cairns
State/Province
Queensland
ZIP/Postal Code
4870
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61499200998
Facility Name
Tasman Oncology Research ( Site 1456)
City
Southport
State/Province
Queensland
ZIP/Postal Code
4215
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+61 7 5613 2480
Facility Name
Royal Adelaide Hospital-RAH Cancer Centre ( Site 1457)
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61870745559
Facility Name
Icon Cancer Centre Hobart ( Site 1465)
City
Hobart
State/Province
Tasmania
ZIP/Postal Code
7000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
61361668308
Facility Name
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1455)
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+6138559500
Facility Name
One Clinical Research ( Site 1460)
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0410565868
Facility Name
Ordensklinikum Linz GmbH Elisabethinen-Dermatologie ( Site 0602)
City
Linz
State/Province
Oberosterreich
ZIP/Postal Code
4020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4373276764508
Facility Name
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0601)
City
Graz
State/Province
Steiermark
ZIP/Postal Code
8036
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4331638581320
Facility Name
Medizinische Universitaet Innsbruck-Univ Klinik für Dermatologie, Venerologie und Allergologie ( Sit
City
Innsbruck
State/Province
Tirol
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4351250481473
Facility Name
Medizinische Universität Wien-Department of Dermatology ( Site 0600)
City
Vienna
State/Province
Wien
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4314040077310
Facility Name
Uniklinikum Salzburg-Department of Dermatology and Allergology ( Site 0604)
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+435725557842
Facility Name
Jessa Ziekenhuis ( Site 0656)
City
Hasselt
State/Province
Limburg
ZIP/Postal Code
3500
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0473 497 669
Facility Name
VITAZ-Medical Oncology ( Site 0654)
City
Sint-Niklaas
State/Province
Oost-Vlaanderen
ZIP/Postal Code
B-9100
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
3293326056
Facility Name
UZ Leuven-General Medical Oncology ( Site 0650)
City
Leuven
State/Province
Vlaams-Brabant
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
3216346900
Facility Name
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 0256)
City
Belo Horizonte
State/Province
Minas Gerais
ZIP/Postal Code
30130090
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5531999785050
Facility Name
Hospital de Cancer de Londrina-Clinical Research Unit ( Site 0252)
City
Londrina
State/Province
Parana
ZIP/Postal Code
86015-520
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+5543999087733
Facility Name
Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 0259)
City
Passo Fundo
State/Province
Rio Grande Do Sul
ZIP/Postal Code
99010-080
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
555421033490
Facility Name
ANIMI - Unidade de Tratamento Oncologico ( Site 0255)
City
Lages
State/Province
Santa Catarina
ZIP/Postal Code
88501001
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
4933805200
Facility Name
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia ( Site 0262)
City
Santo André
State/Province
Sao Paulo
ZIP/Postal Code
09060-870
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
5511974029832
Facility Name
A. C. Camargo Cancer Center ( Site 0258)
City
Sao Paulo
ZIP/Postal Code
01509-010
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+55 11 994270884
Facility Name
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0004)
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
6137377700 ext 70208
Facility Name
Princess Margaret Cancer Centre ( Site 0006)
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
4169464628
Facility Name
Oncocentro Valdivia ( Site 0307)
City
Valdivia
State/Province
Los Rios
ZIP/Postal Code
5112129
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+56992195434
Facility Name
FALP-UIDO ( Site 0303)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
7500921
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
56224457254
Facility Name
Oncovida ( Site 0304)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
7510032
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
56986303096
Facility Name
Clínica UC San Carlos de Apoquindo ( Site 0305)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
7620002
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
56223546919
Facility Name
Bradfordhill-Clinical Area ( Site 0302)
City
Santiago
State/Province
Region M. De Santiago
ZIP/Postal Code
8420383
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+56 9 84859580
Facility Name
ONCOCENTRO APYS-ACEREY ( Site 0300)
City
Viña del Mar
State/Province
Valparaiso
ZIP/Postal Code
2520598
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+56992369820
Facility Name
Centro de Investigación Oncológica del Norte ( Site 0308)
City
Antofagasta
ZIP/Postal Code
1240000
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
56994198125
Facility Name
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 1650)
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613911233048
Facility Name
Chongqing University Cancer Hospital ( Site 1651)
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8615923245950
Facility Name
Fujian Provincial Cancer Hospital ( Site 1659)
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350014
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613859089836
Facility Name
Sun Yat-sen University Cancer Center-melanoma ( Site 1655)
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
15915733209
Facility Name
Guangxi Medical University Affiliated Tumor Hospital ( Site 1668)
City
Nanning
State/Province
Guangxi
ZIP/Postal Code
530021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
18677102309
Facility Name
The Third Hospital of Zhengzhou-Oncology ( Site 1653)
City
Zhengzhou Shi
State/Province
Henan
ZIP/Postal Code
450001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13937130192
Facility Name
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 1664)
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
15807183251
Facility Name
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8615951956162
Facility Name
Jiangsu Province Hospital-Oncology Department ( Site 1663)
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+8613951807457
Facility Name
The First Affiliated Hospital of Nanchang University ( Site 1652)
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
13870051522
Facility Name
The First Hospital of Jilin University-Oncology ( Site 1665)
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613944888991
Facility Name
Fudan University Shanghai Cancer Center ( Site 1658)
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613916860586
Facility Name
Shanxi Bethune Hospital ( Site 1660)
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
02783663425
Facility Name
West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667)
City
Cheng Du
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+86 18980601130
Facility Name
Zhejiang Cancer Hospital-Oncology ( Site 1661)
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8613750851650
Facility Name
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0702)
City
Valence
State/Province
Drome
ZIP/Postal Code
26953
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+33 475757549
Facility Name
Hopital Claude Huriez - CHU de Lille-Clinique de Dermatologie ( Site 0700)
City
Lille
State/Province
Nord-Pas-de-Calais
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
33320444193
Facility Name
Centre Hospitalier de Pau ( Site 0708)
City
PAU
State/Province
Pyrenees-Atlantiques
ZIP/Postal Code
64 000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
33559924848
Facility Name
Gustave Roussy-Dermatologie ( Site 0713)
City
Villejuif
State/Province
Val-de-Marne
ZIP/Postal Code
94800
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
33142114210
Facility Name
Universitaetsklinikum Heidelberg ( Site 0765)
City
Heidelberg
State/Province
Baden-Wurttemberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+49 6221 56-36871
Facility Name
Universitätsmedizin Mannheim ( Site 0751)
City
Mannheim
State/Province
Baden-Wurttemberg
ZIP/Postal Code
68167
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
496213834461
Facility Name
Universitaetsklinikum Erlangen-Hautklinik ( Site 0750)
City
Erlangen
State/Province
Bayern
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0049-9131-8545810
Facility Name
Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0754)
City
Buxtehude
State/Province
Niedersachsen
ZIP/Postal Code
21614
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+49 (0)4161 703 6212
Facility Name
Medizinische Hochschule Hannover ( Site 0758)
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+49 (0) 511 532 7678
Facility Name
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0761)
City
Essen
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00492017232325
Facility Name
Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 0759)
City
Minden
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
32429
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
495717094501
Facility Name
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0766)
City
Dresden
State/Province
Sachsen
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
4935145819782
Facility Name
Universitätsklinikum Leipzig ( Site 0762)
City
Leipzig
State/Province
Sachsen
ZIP/Postal Code
04103
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00493419718600
Facility Name
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 0756)
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+4930450518002
Facility Name
Universitaetsklinikum Hamburg-Eppendorf ( Site 0752)
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+49 (0)40 7410-53651
Facility Name
All India Institute of Medical Sciences-Medical oncology ( Site 1552)
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110029
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
919958975343
Facility Name
Artemis hospital ( Site 1551)
City
Gurugram
State/Province
Haryana
ZIP/Postal Code
122001
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
8377828241
Facility Name
Tata Memorial Hospital-Medical Oncology ( Site 1550)
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400012
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
919920640040
Facility Name
Emek Medical Center-oncology ( Site 0952)
City
Afula
ZIP/Postal Code
1834111
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
97246495723
Facility Name
Soroka Medical Center ( Site 0953)
City
Be'er Sheva
ZIP/Postal Code
8410101
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
97286400797
Facility Name
Rambam Health Care Campus-Oncology Division ( Site 0955)
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
04-777-6700
Facility Name
Hadassah Medical Center ( Site 0951)
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
972505172537
Facility Name
Rabin Medical Center-Oncology ( Site 0954)
City
Petah Tikva
ZIP/Postal Code
4941492
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+972-3-9378077
Facility Name
Sheba Medical Center-ONCOLOGY ( Site 0950)
City
Ramat Gan
ZIP/Postal Code
5265601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
97235302243
Facility Name
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1004)
City
Meldola
State/Province
Emilia-Romagna
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+390543739274
Facility Name
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1000)
City
Milan
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
390223902557
Facility Name
Instituto Tumori Giovanni Paolo II ( Site 1003)
City
Bari
State/Province
Puglia
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+39 0805555138
Facility Name
Azienda Ospedaliero Universitaria Senese ( Site 1005)
City
Siena
State/Province
Toscana
ZIP/Postal Code
53100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
390577586335
Facility Name
Istituto Europeo di Oncologia IRCCS ( Site 1008)
City
Milano
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+390294372754
Facility Name
Nagoya University Hospital ( Site 1753)
City
Nagoya-Shi
State/Province
Aichi
ZIP/Postal Code
466-8560
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
81527441956
Facility Name
Niigata Cancer Center Hospital ( Site 1751)
City
Niigata-shi
State/Province
Niigata
ZIP/Postal Code
951-8566
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
81252665111
Facility Name
Seoul National University Hospital-Oncology ( Site 1600)
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
82220724035
Facility Name
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1601)
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
82222288138
Facility Name
Samsung Medical Center-Division of Hematology/Oncology ( Site 1602)
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+82-2-3410-6820
Facility Name
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1501)
City
Tauranga
State/Province
Bay Of Plenty
ZIP/Postal Code
3112
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
6475798153
Facility Name
New Zealand Clinical Research (Christchurch) ( Site 1509)
City
Christchurch
State/Province
Canterbury
ZIP/Postal Code
8011
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
6433640020
Facility Name
P3 Research - Palmerston North ( Site 1510)
City
Palmerston North
State/Province
Manawatu-Wanganui
ZIP/Postal Code
4414
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
6463508130
Facility Name
Harbour Cancer & Wellness ( Site 1508)
City
Auckland
ZIP/Postal Code
0627
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
6421783590
Facility Name
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1061)
City
Bydgoszcz
State/Province
Kujawsko-pomorskie
ZIP/Postal Code
85-796
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0048523743029
Facility Name
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1058)
City
Siedlce
State/Province
Mazowieckie
ZIP/Postal Code
08-110
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48256403493
Facility Name
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-781
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48226439375
Facility Name
Bialostockie Centrum Onkologii ( Site 1065)
City
Bialystok
State/Province
Podlaskie
ZIP/Postal Code
15-027
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48856646888
Facility Name
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site
City
Gdańsk
State/Province
Pomorskie
ZIP/Postal Code
80-214
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0048585846280
Facility Name
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oncologii, Chemioterapii ( Site 1064)
City
Słupsk
State/Province
Pomorskie
ZIP/Postal Code
76-200
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48604975136
Facility Name
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1056)
City
Gliwice
State/Province
Slaskie
ZIP/Postal Code
44101
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
48784981888
Facility Name
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 1054)
City
Kielce
State/Province
Swietokrzyskie
ZIP/Postal Code
25-734
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+48413674315
Facility Name
Szpital Kliniczny im. H. Swiecickiego nr 2-Oddział Kliniczny Onkologii Klinicznej i Doświadczalnej (
City
Poznan
State/Province
Wielkopolskie
ZIP/Postal Code
60-780
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
48606228277
Facility Name
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 1161)
City
Port Elizabeth
State/Province
Eastern Cape
ZIP/Postal Code
6055
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
27413630581
Facility Name
Medical Oncology Centre of Rosebank ( Site 1160)
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2196
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0824445473
Facility Name
Wilgers Oncology Centre ( Site 1154)
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0040
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+27128072744
Facility Name
Curo Oncology ( Site 1158)
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0084
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+27 82 822 5556
Facility Name
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 1151)
City
Sandton
State/Province
Gauteng
ZIP/Postal Code
2196
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
27118830900
Facility Name
Cape Town Oncology Trials ( Site 1155)
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7570
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
27219443832
Facility Name
Cancercare Rondebosch Oncology-Clinical trials ( Site 1159)
City
Rondebosch
State/Province
Western Cape
ZIP/Postal Code
7700
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
27219443700
Facility Name
Institut Català d'Oncologia - L'Hospitalet ( Site 1202)
City
L'Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08908
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
34932607333
Facility Name
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1203)
City
Doniostia - San Sebastian
State/Province
Gipuzkoa
ZIP/Postal Code
20014
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
34943328315
Facility Name
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1204)
City
Madrid
State/Province
Madrid, Comunidad De
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
(+34) 913368263
Facility Name
H.R.U Málaga - Hospital General-Oncology ( Site 1201)
City
Málaga
State/Province
Malaga
ZIP/Postal Code
29011
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
34951291425
Facility Name
Hospital General Universitario de Valencia ( Site 1200)
City
Valencia
State/Province
Valenciana, Comunitat
ZIP/Postal Code
46014
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
34963131800437635
Facility Name
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1205)
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
34600162731
Facility Name
Länssjukhuset Ryhov-Onkologkliniken ( Site 1253)
City
Jönköping
State/Province
Jonkopings Lan
ZIP/Postal Code
553 05
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
46102429483
Facility Name
Karolinska Universitetssjukhuset Solna ( Site 1252)
City
Solna
State/Province
Stockholms Lan
ZIP/Postal Code
171 64
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
46851770000
Facility Name
University Hospital Basel ( Site 1303)
City
Basel
State/Province
Basel-Stadt
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+41 61 32 8 60 16
Facility Name
Inselspital Bern ( Site 1301)
City
Bern
State/Province
Berne
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
031 632 41 14
Facility Name
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1307)
City
Genève
State/Province
Geneve
ZIP/Postal Code
1211
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
0041223729862
Facility Name
Ospedale Regionale Bellinzona e Valli ( Site 1308)
City
Bellinzona
State/Province
Ticino
ZIP/Postal Code
6500
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00418119411
Facility Name
CHUV (centre hospitalier universitaire vaudois) ( Site 1304)
City
Lausanne
State/Province
Vaud
ZIP/Postal Code
1011
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
41795562698
Facility Name
Hôpital de Sion ( Site 1305)
City
Sion
State/Province
Wallis
ZIP/Postal Code
1951
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
41795567881
Facility Name
UniversitätsSpital Zürich-Dermatology ( Site 1300)
City
Zürich Flughafen
State/Province
Zurich
ZIP/Postal Code
8058
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
41442552588
Facility Name
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 1306)
City
Sankt Gallen
ZIP/Postal Code
9007
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
41714941111
Facility Name
Ankara City Hospital-Medical Oncology ( Site 1357)
City
Cankaya
State/Province
Ankara
ZIP/Postal Code
06800
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905052933234
Facility Name
I.E.U. Medical Point Hastanesi-Oncology ( Site 1360)
City
Izmir, Karsiyaka
State/Province
Izmir
ZIP/Postal Code
009035575
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+905052642353
Facility Name
Hacettepe Universite Hastaneleri ( Site 1363)
City
Ankara
ZIP/Postal Code
06230
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905326880089
Facility Name
Liv Hospital Ankara-Oncology ( Site 1353)
City
Ankara
ZIP/Postal Code
06680
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905056604536
Facility Name
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1355)
City
Antalya
ZIP/Postal Code
07059
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
905052312377
Facility Name
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1358)
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
00905063509061
Facility Name
Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1361)
City
Mersin
ZIP/Postal Code
33240
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+9005458259095
Facility Name
Ondokuz Mayıs Universitesi-Oncology department ( Site 1359)
City
Samsun
ZIP/Postal Code
55139
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
+90 53 25992825
Facility Name
Addenbrooke's Hospital ( Site 1400)
City
Cambridge
State/Province
Cambridgeshire
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
441223274401
Facility Name
University College London Hospital ( Site 1405)
City
London
State/Province
England
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
4402034475085
Facility Name
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 1401)
City
London
State/Province
London, City Of
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Study Coordinator
Phone
07817932416

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
IPD Sharing URL
http://engagezone.msd.com/ds_documentation.php
Links:
URL
https://www.merckclinicaltrials.com/
Description
Merck Clinical Trials Information
URL
https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=7684A-010&&kw=7684A-010
Description
Plain Language Summary

Learn more about this trial

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

We'll reach out to this number within 24 hrs